(lp0
S'RespireRx Pharmaceuticals Inc. Announces 1-for-325 Reverse Stock Split Yahoo Finance - Sep 1, 2016 GLEN ROCK, NJ-- - RespireRx Pharmaceuticals Inc.  , a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory&nbsp;...'
p1
aS'RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE ... Yahoo Finance - Dec 23, 2016 GLEN ROCK, NJ-- - RespireRx Pharmaceuticals Inc.  , is pleased to announce positive results of the PACE  trial&nbsp;...'
p2
aS'RESPIRERX PHARMACEUTICALS INC.  Files An 8-K Entry into a ... Market Exclusive - Mar 16, 2017 RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.'
p3
aS"RespireRx Pharma's CX1739 shows mixed results in mid-stage study in opioid ... Seeking Alpha - Dec 15, 2016 RespireRx Pharmaceuticals  announces data from an 18-subject Phase 2a clinical study assessing the ability of CX1739 to reverse respiratory depression in patients taking a short-acting opioid called remifentanil without altering its ..."
p4
aS'Checking on Shares of RespireRx Pharmaceuticals Inc.  SKV News - 14 hours ago RespireRx Pharmaceuticals Inc.  has a Value Composite Score of 99. Based on a scale from 0 to 100, a score closer to zero would signal an undervalued company and a higher score would represent an expensive or overvalued company.'
p5
aS'RespireRx Pharmaceuticals Inc.  Novel Medicines for Respiratory Diseases ... Investing News Network    - Sep 30, 2016 RespireRx Pharmaceuticals Inc.  is developing small molecule medicines for the treatment of respiratory disease with a focus on sleep apneas and respiratory depression and distress.'
p6
aS"GNC Holdings  Reaches $6.98 Yearly Low; Shorts at RESPIRERX ... Wolcott Daily - Mar 27, 2017 The stock of GNC Holdings Inc  hit a new 52-week low and has $6.63 target or 5.00% below today's $6.98 share price."
p7
aS"FDA Removes Clinical Hold on RespireRx's CX1739 Sleep Review - Mar 3, 2016 RespireRx Pharmaceuticals Inc has received notice that the US Food and Drug Administration  has removed the clinical hold on the company's Investigational New Drug application for CX1739, allowing the initiation of clinical trials."
p8
aS'RespireRx nets mixed results in Phase 2 BioPharma Dive - Dec 16, 2016 New Jersey-based RespireRx Pharmaceuticals on Thursday released mixed results for CX1739, its treatment for opioid-induced respiratory depression and sleep apnea.'
p9
aS'Drug Dronabinol Reduces Symptoms of Obstructive Sleep Apnea, Finds Phase 2B Study Sleep Review - Jan 4, 2017 RespireRx Pharmaceuticals Inc announced positive results of the PACE  trial conducted by David Carley, PhD, and colleagues at the University of Illinois at Chicago and Northwestern University.'
p10
a.